# 2025年12月6日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. 免疫化疗方案对IELSG37试验中原发性纵隔B细胞淋巴瘤患者结局的影响

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/40939190)
**期刊：** Blood
**PMID：** 40939190
**DOI：** 10.1182/blood.2025028823

### 第一部分 原文与翻译

**英文原标题：** Impact of immunochemotherapy regimens on outcomes of patients with primary mediastinal B-cell lymphoma in the IELSG37 trial.

> **英文摘要：**
> The IELSG37 trial enrolled 545 patients with primary mediastinal B-cell lymphoma (PMBCL) and demonstrated that consolidation radiotherapy (RT) can be omitted in patients with complete metabolic response, defined by the Lugano classification as Deauville score (DS) 1 to 3. This report evaluates outcomes after different frontline rituximab- and doxorubicin-based immunochemotherapy regimens chosen according to local practice. Patients treated with R-CHOP21 (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone, administered every 21 days) showed a significantly higher percentage of DS 5 than those on other regimens (23.8% vs 8.2% average; P < .001) and a trend toward additional unplanned treatments (53.2% vs 46.9%; P = .30). The increased risk of poor response was confirmed in a multinomial logistic regression analysis adjusted for age, sex, international prognostic index score, and performance status. R-CHOP21 was also associated with smaller reductions in metabolic tumor volume and less pronounced decreases in maximum standardized uptake value. Patients with DS 5 more often received additional treatment (RT and/or salvage chemotherapy with or without autologous consolidation) after induction immunochemotherapy (96% vs 41%; P < .001) and experienced significantly poorer outcomes. Although differences in progression-free and overall survival between R-CHOP21 and more aggressive regimens were not statistically significant, R-CHOP21 may increase the risk of additional treatments and may be inadvisable as frontline therapy for PMBCL. This trial was registered at www.clinicaltrials.gov as #NCT01599559.

> **中文摘要：**
> IELSG37试验共纳入545例原发性纵隔B细胞淋巴瘤（PMBCL）患者，结果显示，对于达到完全代谢缓解的患者（依卢加诺分类定义的Deauville评分〔DS〕为1至3），可省略巩固放疗（RT）。本报告评估了依据各中心常规选择的不同利妥昔单抗和阿霉素为基础的一线免疫化疗方案后的结局。接受R-CHOP21方案（利妥昔单抗、环磷酰胺、阿霉素、长春新碱及泼尼松，每21天一疗程）治疗的患者，DS 5的比例显著高于其他方案（23.8% vs 平均8.2%；P < .001），并呈现出更多额外非计划治疗的趋势（53.2% vs 46.9%；P = .30）。在经年龄、性别、国际预后指数评分及体能状态调整后的多项逻辑回归分析中，这种不良反应风险升高得到了证实。R-CHOP21还与代谢肿瘤体积降低幅度较小及最大标准摄取值下降不明显相关。与DS 5相关的患者在诱导免疫化疗后更常接受额外治疗（放疗和/或挽救化疗，伴或不伴自体巩固治疗）（96% vs 41%；P < .001），且其结局显著较差。尽管R-CHOP21与更强化方案之间的无进展生存期及总生存期差异未达统计学显著，但R-CHOP21可能增加额外治疗的风险，因此或不适宜作为PMBCL的一线治疗方案。该试验注册于www.clinicaltrials.gov，编号为NCT01599559。

### 第二部分 AI 大师评价

本研究基于IELSG37试验，探讨不同免疫化疗方案对原发性纵隔B细胞淋巴瘤患者的疗效影响。结果表明，使用R-CHOP21方案的患者代谢应答较差，额外治疗比例更高，提示该方案可能不适合作为首选治疗。该研究结合多因素回归分析，控制了重要临床变量，证实了R-CHOP21疗效不足的趋势。创新之处在于首次在大样本随机研究中比较不同免疫化疗方案的代谢学和临床结局，但其局限性包括不同中心方案选择的非随机性及部分统计差异未达显著。

---

## 2. 血小板因子4调控造血干细胞衰老

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/40920871)
**期刊：** Blood
**PMID：** 40920871
**DOI：** 10.1182/blood.2024027432

### 第一部分 原文与翻译

**英文原标题：** Platelet factor 4 regulates hematopoietic stem cell aging.

> **英文摘要：**
> Hematopoietic stem cells (HSCs) responsible for blood cell production and their bone marrow regulatory niches undergo age-related changes, affecting immune responses and predisposing individuals to hematologic malignancies. Here, we show that the age-related alterations of the megakaryocytic niche and associated downregulation of platelet factor 4 (PF4) are pivotal mechanisms driving HSC aging. PF4-deficient mice display several phenotypes reminiscent of accelerated HSC aging, including lymphopenia, increased myeloid output, and DNA damage, mimicking physiologically aged HSCs. Remarkably, recombinant PF4 administration restored old HSCs to youthful functional phenotypes characterized by improved cell polarity, reduced DNA damage, enhanced in vivo reconstitution capacity, and balanced lineage output. Mechanistically, we identified low-density lipoprotein receptor and C-X-C motif chemokine receptor 3 as HSC receptors transmitting the PF4 signal, with double knockout mice exhibiting exacerbated HSC aging phenotypes similar to PF4-deficient mice. Furthermore, human HSCs across various age groups also respond to the youthful PF4 signaling, highlighting its potential for rejuvenating aged hematopoietic systems. These findings pave the way for targeted therapies aimed at reversing age-related HSC decline, with potential implications in the prevention or improvement of the course of age-related hematopoietic diseases.

> **中文摘要：**
> 造血干细胞（HSCs）负责血细胞的生成，其在骨髓中的调控性微环境会随着年龄变化而发生改变，这种变化影响免疫应答，并使个体易患血液系统恶性肿瘤。本文显示，巨核细胞龛的年龄相关改变及随之发生的血小板因子4（PF4）下调，是驱动HSC衰老的关键机制。PF4缺失小鼠表现出多种类似于HSC加速衰老的表型，包括淋巴细胞减少、髓系产物增加以及DNA损伤，这些特征与生理性衰老HSC高度相似。值得注意的是，外源性重组PF4的给药可使老龄HSC恢复年轻化的功能特征，包括改善细胞极性、减少DNA损伤、增强体内重建能力以及平衡的谱系分化输出。从机制上看，研究确定低密度脂蛋白受体和C-X-C基序趋化因子受体3是介导PF4信号的HSC受体，双基因敲除小鼠表现出与PF4缺失类似的加重HSC衰老表型。此外，不同年龄组的人HSC也能响应具有年轻特征的PF4信号，这突显了其在重塑老化造血系统方面的潜力。这些发现为逆转HSC年龄相关功能衰退的靶向治疗提供了基础，并对预防或改善与年龄相关的造血疾病具有重要启示意义。

### 第二部分 AI 大师评价

本研究揭示了血小板因子4在造血干细胞衰老中的关键调控作用。作者通过小鼠模型和人源HSC实验，发现PF4的降低是驱动HSC衰老的重要机制，而补充PF4可逆转老化干细胞的功能缺陷。研究创新性地确定了PF4信号传递的受体通路，为开发延缓或逆转造血衰老的治疗策略提供了新方向。尽管仍需进一步验证其长期安全性和临床可行性，但该研究在干细胞衰老调控领域具有重要突破意义。

---

速递结束，祝您工作愉快！